myeloma Archives -

Sanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38

Sanofi trumpets Darzalex rival isatuximab in refractory myeloma

https://pharmaphorum.com/news/sanofi-darzalex-rival-isatuximab-refractory-myeloma/

US biotech Mustang Bio says that an investigator-led trial of its CAR-T therapy for multiple myeloma – the

Mustang Bio’s first-of-a-kind CAR-T starts trials

https://pharmaphorum.com/news/mustang-bio-car-t-starts-trials/

Over the last decade, treatments for the blood cancer myeloma have come on in leaps and bounds –

Listening to the myeloma patient voice is difficult – but it still needs to be done

https://pharmaphorum.com/views-analysis-patients/listening-myeloma-patient-voice-difficult-but-needs-to-be-done/

Research-based charities are taking on an ever-growing role in frontline clinical research, and Myeloma UK has just launched

Myeloma UK launches stratified medicine trial of Darzalex combo

https://pharmaphorum.com/news/myeloma-uk-launches-stratified-medicine-trial-darzalex-combo/

Kyprolis gains label expansion in Europe

Amgen’s Kyprolis gains expanded myeloma use in Europe

https://pharmaphorum.com/transversal-categories/uk-and-europe/amgens-kyprolis-gains-expanded-myeloma-use-europe/

Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its

Further Darzalex results extend hope for PFS in Myeloma

https://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/

myeloma